Zolitrat

Zolitrat (Anastrozole) is an oral aromatase inhibitor used primarily in hormone receptor-positive breast cancer therapy. This non-steroidal medication helps reduce estrogen levels in postmenopausal women. Suitable for metastatic and adjuvant treatment settings. Consult a healthcare professional for suitability.

Zolitrat is prescribed to treat hormone receptor-positive breast cancer in postmenopausal women. It works by lowering estrogen levels, which can slow or stop the growth of cancer cells. This medication is often used after surgery or as part of ongoing therapy. Patients may also receive it for advanced or metastatic breast cancer.

Zolitrat is taken orally and may help manage cancer progression by reducing estrogen production. Common effects include hot flashes, joint pain, and fatigue. Some users report mood changes or mild gastrointestinal discomfort. These effects vary by individual and should be monitored by a healthcare provider.

Zolitrat should be handled with care, especially by individuals who may be pregnant or breastfeeding. Keep the medication in a secure, dry place away from children. Regular medical check-ups are recommended to monitor treatment progress and adjust therapy as needed. Report any unusual symptoms to a healthcare professional promptly.

Zolitrat may interact with other medications that affect estrogen levels or hormone therapies. Caution is advised when using alcohol or herbal supplements during treatment. Certain antidepressants, tamoxifen, and CYP3A4 inhibitors may alter its effectiveness. Always inform your doctor about all medications and supplements you are taking.